Organization
Pitié Salpêtrière Hospital
5 abstracts
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.Org: Memorial Sloan Kettering Cancer Center, Sorbonne University and Saint-Antoine Hospital, Pitié Salpêtrière Hospital, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, APHP.Centre - Université Paris Cité, Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
2007 UPDATE OF THE FRENCH NATIONAL GUIDELINES FOR THE USE IN DAILY PRACTICE OF TNF-BLOCKERS IN PEOPLE SUFFERING FROM RHEUMATOID ARTHRITISOrg: University of Paris 6, Pitié Salpêtrière Hospital, Immuno Rheumatology, CHU Montpellier, CHU Marseille,
Abstract
BARRIERS TO PHYSICAL ACTIVITY COLLECTED BY THE IFAB QUESTIONNAIRE CORRELATE WITH LEVELS OF PHYSICAL ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS OR SPONDYLOARTHRITIS: A CROSS-SECTIONAL STUDY OF 150 PATIENTSOrg: Sorbonne Université, Inserm U567, Institut Pierre Louis d’Épidémiologie et de Santé Publique, PEPITES, Hôpital Charles Nicolle,